References
- Arezki C., Garofalo M., Gad B., Staniszewska M., Chiaro J., Pancer K., Kuryk L.: Cancer vaccines: an update on recent achievements and prospects for cancer therapy. Clin. Exp. Med., 25, 24 (2025) DOI: 10.1007/s10238-024-01541-7
- Bessis N., GarciaCozar F.J., Boissier M.C.: Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther., 11, S10–S17 (2004) DOI: 10.1038/sj.gt.3302364
- Boutin C, Walker B, and Ramirez J. Advances in immune checkpoint blockade for mesothelioma: What have we learned? Front Oncol. 11, 632712 (2021) DOI: 10.1002/cncr.33433
- Chiaro J., Antignani G., Feola S., Feodoroff M., Martins B., Co-joc H., Russo S., Fusciello M., Hamdan F., Ferrari V., Ciampi D., Ilonen I., Räsänen J., Mäyränpää M., Partanen J., Koskela S., Honkanen J., Halonen J., Kuryk L., Rescigno M., Grönholm M., Branca R.M., Lehtiö J., Cerullo V.: Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. Nat. Commun., 14, 7056 (2023) DOI: 10.1038/s41467-023-42668-7
- Garofalo M., Bertinato L., Staniszewska M., Wieczorek M., Salmaso S., Schrom S., Caliceti P., Kuryk L.: Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model. Pharmaceutics 13, 547 (2021) DOI: 10.3390/pharmaceutics13040547
- Garofalo M., Pancer K.W., Wieczorek M., Staniszewska M., Salmaso S., Caliceti P., Kuryk L.: From immunosuppression to immunomodulation – turning cold tumours into hot. J. Cancer, 13, 2884–2892 (2022) DOI: 10.7150/jca.71992
- Garofalo M., Wieczorek M., Anders I., Staniszewska M., Łazniewski M., Prygiel M., Zasada A., Rinner B., Kuryk L.: Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced ranti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model. Front. Oncol., 13, 1259314 (2023) DOI: 10.3389/fonc.2023.1259314
- Pisani P., Airoldi M., Allais A., Aluffi Valletti P., Battista M., Benazzo M., Briatore R., Cacciola S., Cocuzza S., Colombo A., et al.: Metastatic disease in head & neck oncology. Acta Otorhinolaryngol. Ital., 40 (Suppl. 1), S1–S86 (2020) DOI: 10.14639/0392-100X-suppl.1-40-2020
- Jones A, White M, and Chen P. Immune checkpoint inhibitors combined with oncolytic virotherapy: Current perspectives and future prospects. J Immunother Cancer. 9(4), e001230 (2021) DOI: 10.4274/MMJ.galenos.2023.29599
- Kuryk L., Haavisto E., Garofalo M., Capasso C., Hirvinen M., Pesonen S., Cerullo V., Alemany R., Hemminki A.: Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int. J. Cancer, 139, 1883–1893 (2016) DOI: 10.1002/ijc.30228
- Kuryk L., Møller A.S.W.: Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models. Mol. Ther. Oncolytics, 28, 158–169 (2023) DOI: 10.1016/j.omto.2023.01.002
- Kuryk L., Rodella G., Staniszewska M., Pancer K.W., Wieczorek M., Salmaso S., Caliceti P., Garofalo M.: Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front. Oncol., 12, 916839 (2022) DOI: 10.3389/fonc.2022.916839
- Biegert G.W.G., Shaw A.R., Suzuki M.: Current development in adenoviral vectors for cancer immunotherapy. Mol. Ther. Oncolytics, 23, 571–581 (2021) DOI: 10.1016/j.omto.2021.11.014
- Ponce S., Cedrés S., Ricordel C., Isambert N., Viteri S., Herrera-Juarez M., Martinez-Marti A., Navarro A., Lederlin M., Serres X., et al.: ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J. Immunother. Cancer, 11(9), e007552 (2023) DOI: 10.1136/jitc-2023-007552
- Wadowski B., De Rienzo A., Bueno R.: The molecular basis of malignant pleural mesothelioma. Thorac. Surg. Clin., 30(4), 383–393 (2020) DOI: 10.1016/j.thorsurg.2020.08.005
- Zheng M., Huang J., Tong A., Yang H.: Oncolytic viruses for cancer therapy: barriers and recent advances. Mol. Ther. Oncolytics, 15, 234–247 (2019) DOI: 10.1016/j.omto.2019.10.007
- Muravyeva A., Smirnikhina S.: Strategies for modifying adenoviral vectors for gene therapy. Int. J. Mol. Sci., 25(22), 12461 (2024) DOI: 10.3390/ijms252212461
- Treasure T., Lang-Lazdunski L., Waller D., Bliss J.M., Tan C., Entwisle J., Senan S., O’Brien M., Thomas G., Gower N., Darlison L., et al.: Extra-pleural pneumonectomy versus no surgery for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomized controlled trial. Lancet Oncol., 12, 763–772 (2011) DOI: 10.1016/S1470-2045(11)70149-8
- Wu B., Zhang B., Li B., Wu H., Jiang M.: Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther., 9, 274 (2024) DOI: 10.1038/s41392-024-01979-x